TFCP
GALT icon

Twin Focus Capital Partners’s Galectin Therapeutics GALT Stock Holding History

Twin Focus Capital Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-107,363
Closed -$1.07M – 86
2013
Q3 		$1.07M Sell
107,363
-76,914
-42% -$519K 1.02% 16
2013
Q2 		$783K Buy
+184,277
New +$755K 0.8% 22

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Twin Focus Capital Partners's GALT Position: Q4 2013 in Review

Twin Focus Capital Partners sold out of Galectin Therapeutics (GALT) in Q4 2013, closing a stake of 107,363 shares — an estimated $1.07M sold.

Twin Focus Capital Partners first reported a position in GALT in Q2 2013 and held it in 2 quarters. The position peaked at $1.07M in Q3 2013. 33 funds tracked by Wall St. Rank hold GALT as of Q4 2013.

  • Twin Focus Capital Partners reported no remaining Galectin Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Twin Focus Capital Partners sold 107,363 Galectin Therapeutics shares in Q4 2013, an estimated $1.07M.
  • Twin Focus Capital Partners first reported a position in Galectin Therapeutics in Q2 2013 and held it in 2 quarters.
  • Twin Focus Capital Partners's Galectin Therapeutics position peaked at $1.07M in Q3 2013.
  • 33 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2013.

Based on Twin Focus Capital Partners's 13F filing for Q4 2013, filed 18 Feb 2014.